** Travere Therapeutics TVTX.O shares up 0.4% to $44.94 early Thurs after above-target financing

** San Diego, California-based biopharma late Weds announced pricing private offering of $475 mln 0.5% convertible bonds (CBs) due 2032

** Offering size increased from $400 mln; initial conversion price of $64.90 is 45% above stock's last close of $44.76

** Co intends to use approx $350.9 mln of net offering proceeds to repurchase $221.4 mln of its outstanding 2.25% CBs due 2029

** Remaining proceeds earmarked for general purposes, including expenses for commercialization, clinical trial and R&D, capex, among other purposes

** TVTX has roughly $4 bln market cap

** On Apr 13, the U.S. FDA approved expanded use of co's drug, Sparsentan, to treat a rare kidney disorder; TVTX's stock surged 37% in the ensuing session

** With the move on Thurs, stock up about 17% YTD and roughly 50% over the past three months

** 14 of 15 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $55, per LSEG data